Retrospective study of paraneoplastic neurological syndromes in a Chinese Han population from Shandong, East China

ABSTRACT Objective: To analyze the clinical features, diagnostic strategies and therapeutic methods associated with paraneoplastic neurological syndromes. Methods: A retrospective study of paraneoplastic neurological syndromes was performed at a single center in Shandong, East China. The medical records and follow-up data of 28 patients were intensively reviewed between February 2011 and December 2014. Results: Twenty-four (85.7%) patients experienced subacute or chronic onset of disease, and the most common symptoms reported were mild myasthenia and paresthesias. Twenty-five (89.3%) patients presented nervous system lesions prior to occult tumors, and the median time frame between paraneoplastic neurological syndromes onset and the diagnosis of a tumor was 15 weeks. Sensorimotor neuropathy, Lambert-Eaton myasthenic syndrome and limbic encephalitis were the three most common neurological syndromes reported. Elevated serum tumor markers were observed in 44.0% of patients, while 40.7% of patients were positive for onconeural antibodies. Tumors were detected in 21 (75.0%) patients after repeated whole-body screening, and lung carcinomas were the most common primary tumor detected. Seventeen patients received anti-tumor or immunological therapy, and clinical symptoms were relieved in 13 (76.5%) of these patients. Conclusions: In the majority of paraneoplastic neurological syndromes patients, the onset of disease is subacute or chronic with mild clinical symptoms. Nervous system lesions usually occur prior to occult tumors with complicated and various clinical manifestations. Neither tumor markers nor onconeural antibodies exhibit a high rate of occurrence, while repeated whole-body screening is helpful in identifying occult tumors. Early diagnosis and treatment are crucial to these patients.

[1]  S. Minami,et al.  Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer , 2018, Case Reports in Neurology.

[2]  C. Bolton,et al.  Review of the Diagnostic Challenges of Lambert–Eaton Syndrome Revealed Through Three Case Reports , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[3]  M. Rosenfeld,et al.  Update on neurological paraneoplastic syndromes , 2015, Current opinion in oncology.

[4]  C. Chapman,et al.  Paraneoplastic neurologic disorders in small cell lung carcinoma , 2015, Neurology.

[5]  J. Antoine Peripheral neuropathies associated with antibodies directed to intracellular neural antigens. , 2014, Revue neurologique.

[6]  C. Probst,et al.  Anti-neuronal autoantibodies: Current diagnostic challenges. , 2014, Multiple sclerosis and related disorders.

[7]  R. Liblau,et al.  Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies , 2013, Oncoimmunology.

[8]  J. Dalmau,et al.  Antibody Repertoire in Paraneoplastic Cerebellar Degeneration and Small Cell Lung Cancer , 2013, PloS one.

[9]  J. Dalmau,et al.  Paraneoplastic neurological syndromes. , 1988, Cancer Investigation.

[10]  J. Meulstee,et al.  EEG Leading to the Diagnosis of Limbic Encephalitis , 2012, Clinical EEG and neuroscience.

[11]  J. Verschuuren,et al.  Lambert–Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies , 2011, The Lancet Neurology.

[12]  C. Vedeler,et al.  Onconeural antibodies in patients with neurological symptoms: detection and clinical significance , 2011, Acta neurologica Scandinavica. Supplementum.

[13]  R. Balice-Gordon,et al.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis , 2011, The Lancet Neurology.

[14]  J. Honnorat,et al.  Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force , 2011, European journal of neurology.

[15]  R. Balice-Gordon,et al.  Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series , 2010, The Lancet Neurology.

[16]  M. Rosenfeld,et al.  Update on paraneoplastic neurologic disorders. , 2010, The oncologist.

[17]  D. Lanska Adams and Victor’s Principles of Neurology , 2010 .

[18]  J. Dalmau,et al.  Antibodies and neuronal autoimmune disorders of the CNS , 2010, Journal of Neurology.

[19]  J. Honnorat,et al.  Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. , 2010, Archives of neurology.

[20]  D. Friedman,et al.  Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen , 2010, The Lancet Neurology.

[21]  R. Kalb,et al.  AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location , 2009, Annals of neurology.

[22]  Xiaoyu Peng,et al.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies , 2008, The Lancet Neurology.

[23]  J. Honnorat,et al.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[24]  E. Sher,et al.  Electrophysiological differences in seropositive and seronegative Lambert–Eaton myasthenic syndrome , 2007, Muscle & nerve.

[25]  Josep Dalmau,et al.  Paraneoplastic anti–N‐methyl‐D‐aspartate receptor encephalitis associated with ovarian teratoma , 2007, Annals of neurology.

[26]  J. Honnorat,et al.  Recommended diagnostic criteria for paraneoplastic neurological syndromes , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  V. Lennon,et al.  Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. , 2003, Mayo Clinic proceedings.

[28]  R. Darnell,et al.  Paraneoplastic syndromes involving the nervous system. , 2003, The New England journal of medicine.

[29]  R. Hughes Regular review: Peripheral neuropathy , 2002 .

[30]  S. Chokroverty,et al.  Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert–Eaton myasthenic syndrome: Summary statement , 2001, Muscle & nerve.

[31]  G. Escaramís,et al.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. , 2001, Brain : a journal of neurology.

[32]  M. Magistris,et al.  Paraneoplastic anti‐CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy , 2001, Annals of neurology.

[33]  E. Benarroch,et al.  CRMP‐5 neuronal autoantibody: Marker of lung cancer and thymoma‐related autoimmunity , 2001, Annals of neurology.

[34]  S. Gultekin,et al.  Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. , 2000, Brain : a journal of neurology.

[35]  J. Darnell,et al.  Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. , 2000, Cancer research.

[36]  P. O'Suilleabhain,et al.  Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. , 1995, The New England journal of medicine.

[37]  M. Rosenblum,et al.  Paraneoplastic cerebellar degeneration. , 1992, Neurology.

[38]  S. Takahashi,et al.  Lambert-Eaton myasthenic syndrome , 1990, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[39]  N. Murray,et al.  The Lambert-Eaton myasthenic syndrome. A review of 50 cases. , 1988, Brain : a journal of neurology.

[40]  A. Vincent,et al.  Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line , 1985, Nature.

[41]  M. Kurabayashi,et al.  Anti-Hu Antibody-associated Paraneoplastic Neurological Syndrome Showing Peripheral Neuropathy and Atypical Multifocal Brain Lesions. , 2015, Internal medicine.

[42]  R. Hughes,et al.  Peripheral neuropathy. , 1982, The New England journal of medicine.